Skip to main content
    P

    Pulse Biosciences Inc (PLSE)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $46.36
    -4.08 (-8.09%)

    Market Cap: $3.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Pulse Biosciences Inc (PLSE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Pulse Biosciences reported revenue of $350.00K for the fiscal year ended Dec 31, 2025. That year, net income was -$72.78M with a net margin of -20794.6%, operating cash flow was -$54.12M and free cash flow was -$54.44M. The quarter ended Sep 30, 2026 had revenue of $395.00K and net income of -$23.05M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $68.00K, a compound annual rate of 20.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$350.00KN/A-54.0%-21982.6%-20794.6%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$700.00K-50.6%-1606.3%-8293.9%-8357.9%
    Dec 2021$1.42MN/A-38.8%-4443.9%-4489.4%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$446.00K+80.6%100.0%-8418.2%-8418.2%
    Dec 2017$247.00K+263.2%100.0%-10351.0%-10351.0%
    Dec 2016$68.00KN/A100.0%-13997.1%-13997.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$350.00K$0$0$700.00K$1.42M$0$0$446.00K$247.00K$68.00K
    Cost of revenue$539.00K$0$0$11.94M$1.97M$0$0$0$0$0
    Gross profit-$189.00K$0$0-$11.24M-$550.00K$0$0$446.00K$247.00K$68.00K
    Research and development$44.72M$32.34M$27.80M$20.84M$28.64M$26.44M$24.96M$17.25M$9.65M$5.51M
    Operating income-$76.94M-$56.26M-$43.57M-$58.06M-$63.01M-$49.97M-$47.95M-$37.55M-$25.57M-$9.52M
    Net income-$72.78M-$53.59M-$42.21M-$58.51M-$63.66M-$49.85M-$46.97M-$37.55M-$25.57M-$9.52M
    EBITDA-$75.92M-$55.10M-$42.37M-$56.70M-$61.85M-$48.87M-$47.31M-$36.38M-$24.54M-$8.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$395.00K$434.00K$401.00K$264.00K$86.00K$0$0$1.66M$0$0$0$1.74M
    Gross profit$204.00K$161.00K$31.00K$4.00K-$193.00K$0$0$832.00K$0$0$0$1.44M
    Operating income-$24.29M-$25.27M-$19.15M-$18.25M-$20.37M-$20.27M-$18.04M-$20.26M-$13.65M-$11.73M-$10.62M-$12.53M
    Net income-$23.05M-$24.66M-$18.58M-$17.43M-$19.39M-$19.17M-$16.80M-$19.39M-$12.68M-$11.38M-$10.14M-$11.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.57M by $79.17M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$94.54M$132.46M$59.15M$77.88M$59.15M$41.29M$41.91M$70.64M$49.82M$26.31M
    Current assets$83.42M$119.45M$45.33M$62.15M$45.33M$22.34M$26.40M$60.36M$38.48M$16.66M
    Cash and equivalents$80.73M$118.04M$44.37M$61.14M$44.37M$12.46M$6.90M$51.10M$3.39M$2.09M
    Total liabilities$13.88M$17.60M$14.79M$80.13M$14.79M$18.40M$11.18M$4.31M$3.83M$1.02M
    Short-term debt$1.57M$1.35M$1.06M$917.00K$1.21M$0N/AN/AN/AN/A
    Long-term debtN/AN/AN/A$65.00MN/AN/AN/AN/A$0$0
    Shareholder equity$80.66M$114.86M$44.36M-$2.25M$44.36M$22.89M$30.74M$66.33M$45.99M$25.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$201.58M$115.56M$81.62M$96.11M$108.77M$120.25M$133.38M$132.46M$93.05M$40.43M$49.16M$59.15M
    Total liabilities$18.01M$16.06M$15.32M$15.46M$16.07M$15.76M$14.93M$17.60M$13.91M$13.46M$12.88M$14.79M
    Cash and equivalents$36.73M$101.62M$68.32M$80.73M$95.21M$106.35M$119.28M$118.04M$79.03M$26.20M$34.88M$44.37M
    Shareholder equity$183.57M$99.50M$66.30M$80.66M$92.69M$104.49M$118.45M$114.86M$79.13M$26.97M$36.29M$44.36M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$54.12M-$36.34M-$33.04M-$47.01M-$54.10M-$35.37M-$34.19M-$23.90M-$11.09M-$8.05M
    Capital expenditures$315.00K$125.00K$121.00K$401.00K$437.00K$441.00K$608.00K$276.00K$2.55M$64.00K
    Free cash flow-$54.44M-$36.47M-$33.16M-$47.41M-$54.53M-$35.81M-$34.79M-$24.17M-$13.64M-$8.12M
    Dividends paidN/AN/AN/AN/A$810.00KN/A$619.00KN/A$0$0
    Share repurchases$0$281.00K$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$335.00K-$125.00K-$121.00K-$401.00K$7.56M$10.04M-$10.10M$26.12M-$23.00M-$14.38M
    Financing cash flow$17.15M$110.14M$16.39M$79.94M$62.69M$30.89M$82.00K$45.50M$35.38M$20.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.27M-$18.71M-$14.60M-$14.76M-$13.04M-$12.81M-$13.52M-$9.14M-$9.02M-$8.39M-$9.78M-$6.78M
    Capital expenditures$142.00K$90.00K$33.00K$105.00K$62.00K$103.00K$45.00K$53.00K$38.00K$29.00K$5.00K$43.00K
    Free cash flow-$15.41M-$18.80M-$14.63M-$14.86M-$13.10M-$12.91M-$13.57M-$9.20M-$9.06M-$8.42M-$9.79M-$6.83M
    Last 12 quarters

    Frequently Asked Questions About PLSE

    What is Pulse Biosciences' annual revenue?

    Pulse Biosciences reported revenue of $350.00K for the fiscal year ended Dec 31, 2025.

    Is Pulse Biosciences profitable?

    No. Pulse Biosciences reported net income of -$72.78M for the fiscal year ended Dec 31, 2025, with a net margin of -20794.6%.

    How much free cash flow does PLSE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$54.12M minus capital expenditures of $315.00K produced free cash flow of -$54.44M.

    How much debt does Pulse Biosciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.57M and cash and equivalents of $80.73M.

    What is PLSE's profit margin?

    For the fiscal year ended Dec 31, 2025, Pulse Biosciences reported gross margin of -54.0%, operating margin of -21982.6% and net margin of -20794.6%.